Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers innovative human therapeutics worldwide. The company played a pivotal role in establishing the biotechnology industry and continues to be at the cutting edge of innovation, leveraging technology and human genetic data to push the boundaries of scientific understanding. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines designed to treat cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.

Amgen is recognized as one of the 30 companies that comprise the Dow Jones Industrial Average® and is also a component of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market, based on market capitalization. The company operates across multiple therapeutic areas, serving healthcare providers globally, including physicians, clinics, dialysis centers, hospitals, and pharmacies through various distribution channels.

Key Products Portfolio

The company's principal products are aimed at addressing significant unmet medical needs:

- Enbrel: Used for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.

- Otezla: Treats adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.

- Prolia: For the treatment of postmenopausal women with osteoporosis.

- XGEVA: Used for the prevention of skeletal-related events.

- Repatha® (evolocumab): Reduces the risks of myocardial infarction, stroke, and coronary revascularization.

- Nplate®: Treats patients with immune thrombocytopenia.

- KYPROLIS®: Used to treat patients with relapsed or refractory multiple myeloma.

- Aranesp®: Treats anemia by increasing the number of red blood cells.

- EVENITY® (romosozumab-aqqg): For the treatment of osteoporosis in postmenopausal men and women.

- Vectibix®: Treats patients with wild-type RAS metastatic colorectal cancer.

- BLINCYTO® (blinatumomab): Used for the treatment of patients with acute lymphoblastic leukemia.

- TEPEZZA®: Treats thyroid eye disease.

Recent Drug Launches

- IMDELLTRA® (tarlatamab-dlle): This is a first-in-class delta-like ligand 3 (DLL3) targeting BiTE molecule. In 2024, IMDELLTRA received accelerated approval in the U.S. for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have disease progression on or after platinum-based chemotherapy. Subsequent marketing authorizations have been granted in Japan and other countries, including Canada, Brazil, Israel, and Great Britain.

Financial Performance

2024 Full Year Results

In 2024, Amgen reported total revenue of $33.42 billion, representing an increase of 18.57% compared to the previous year's revenue of $28.19 billion. For the fourth quarter of 2024, total revenues increased by 11% to $9.1 billion, up from $8.2 billion in the fourth quarter of 2023. Product sales grew by 11%, primarily driven by a 14% volume growth.

Q1 2025 Performance Highlights

Key product performance highlights for the first quarter of 2025 include:

- Fourteen products delivered at least double-digit sales growth in the quarter.

- Notable growth drivers included Repatha® (evolocumab), BLINCYTO® (blinatumomab), TEZSPIRE® (tezepelumab-ekko), EVENITY® (romosozumab-aqqg), TAVNEOS® (avacopan), and UPLIZNA® (inebilizumab-cdon).

- The launch of IMDELLTRA® (tarlatamab-dlle) generated $81 million in sales during the quarter.

Q2 2025 Results Highlights

- Second quarter results showed significant growth, with EVENITY® (romosozumab-aqqg) sales increasing 32% year-over-year to $518 million, primarily driven by volume growth.

Research & Development Pipeline

With strong global performance, Amgen is making substantial investments in its rapidly advancing pipeline to deliver innovative therapies across its four key therapeutic areas. The company has several ongoing clinical trials and strategic R&D initiatives:

- Blinatumomab Subcutaneous Administration: The company plans to advance blinatumomab's subcutaneous administration to a potentially registration-enabling Phase 2 portion of its study, with initiation anticipated in H2 2025.

- Small Cell Lung Cancer (SCLC) Program: Amgen is advancing a comprehensive, global clinical development program for small cell lung cancer (SCLC), including both extensive-stage and limited-stage indications. DeLLphi-304, a Phase 3 study of IMDELLTRA in second-line ES-SCLC, is ongoing, with a data readout anticipated in H1 2025.

Recent Investments

Amgen announced plans to invest more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. This significant investment underscores the company's commitment to expanding its research capabilities and maintaining its competitive edge in biotechnology innovation.

Dividend Information

- Stock Ticker: AMGN

- Exchange: NASDAQ

- Current Price: $273.70 (As of SEP 16, 08:17 AM EDT)

- Dividend (Forward): $9.52

- Dividend Frequency: Quarterly

- Amgen maintains a strong dividend yield, reflecting its commitment to returning value to shareholders through regular payouts.

Strategic Partnerships

Amgen has established numerous collaboration agreements designed to enhance its research capabilities and expand its therapeutic reach. The company actively works with various partners, including:

- Novartis

- UCB

- Bayer HealthCare

- BeiGene

- Eli Lilly

These collaborations are focused on advancing drug development programs across different therapeutic areas, fostering innovation and expanding the company's portfolio of potential treatments.

Amgen continues to focus on innovation while maintaining strong operational performance across its diversified product portfolio. With its established market position, robust pipeline, and strategic investments in research and development, Amgen remains well-positioned for continued success and leadership in the global biotechnology landscape.